Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kap. 4: Lymphoplasmozytisches Lymphom (einschließlich Morbus Waldenström)

Autor/en: Michael Herold
Letzte Änderung: 30.04.2011
  • Buske C et al.
    The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
    Leukemia 2009;23:153-161. PMID:18818699
    [Medline]


  • Coupland SE, Dallenbach FE, Stein H.
    Kleinzellige B-Zell-Lymphome: Differentialdiagnostische Leitlinien.
    Pathologe 2000;21:147-161. PMID:10840820
    [Medline]


  • Dimopoulos MA et al.
    Primary therapy of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine.
    J Clin Oncol 1994;12:2694-2698. PMID:7989946
    [Medline]


  • Dimopoulos M et al.
    Primary treatment of Waldenstrom’s macroglobulinemia (WM) with deaxamethason, rituximab and cyclophosphamide.
    Blood (ASH Annual Meeting Abstracts) 2006 108: Abstract 128
    http://abstracts.hematologylibrary.org/cgi/content/abstract/108/11/128


  • Foran JM et al.
    Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmozytoid lymphoma, Waldenström’s macroglobulinemia and mantle cell lymphoma.
    J ClinOncol 1999;17:546-553. PMID:10080598
    [Medline]


  • Kantarjian HM et al.
    Fludarabine therapy in macroglobulinemic lymphoma.
    Blood 1990;75:1928-1931. PMID:1692487
    [Medline]


  • Kristinsson SY et al.
    Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.
    Blood 2008;112:3052-3056. PMID:18703425
    [Medline]


  • Lai R, Weiss LM.
    Hepatitis C virus and non-Hodgkin’s lymphoma.
    Am J Pathol 1998;109:508-510. PMID:9576565
    [Medline]


  • Leblond V et al.
    Activity in previously treated Waldenström’s macroglobulinemia: a report on 71 cases.
    J Clin Oncol 1998;16:2060-2064. PMID:9626204
    [Medline]


  • Morel P et al.
    International prognostic scoring system for Waldenström macroglobulinemia.
    Blood 2009;113:4163­-4170. PMID:19196866
    [Medline]


  • Swerdlow SH et al.
    Lymphoplasmozytic lymphoma.
    In: Swerdlow SH et al. (Eds).
    WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 194-195.
    WHO Press, Geneva, 2008


  • The Non-Hodgkin’s Lymphoma Classifikation Project.
    A clinical evaluation of the international lymphoma study group classification of Non-Hodgkin’s Lymphoma.
    Blood 1997;89:3909-3918. PMID:9166827
    [Medline]


  • Treon SP.
    How I treat Waldenstrom’s macroglobulinemia.
    Blood 2009;114:2375-2385. PMID:19617573
    [Medline]


  • Treon SP et al.
    Update on treatment recommendations from the Third International Workshop on Waldenstrom’s macroglobulinemia.
    Blood 2006;107:3442-3446. PMID:16410453
    [Medline]


  • Waldenström J.
    Incipient myelomatosis or “essential” hyperglobulinemia with fibrinogenopenia: a new syndrom ?
    Acta Med Scand 1944;117:216-222.


  • Zinzani PL et al.
    Fludarabine treatment in resistant Waldenstrom’s macroglobulinemia.
    Eur J Haematol 1995;54:49-52. PMID:7698295
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag [Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]